Solid Biosciences Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript
Good afternoon. It's now my pleasure to introduce Kevin Tan, CFO; Paul Herzich, CTO; and Brian Collins, SVP at Solid. Thank you all for joining us today. The format for this session, roughly a 25 minutes fireside chat. (Operator Instructions) And to start off, perhaps you could give us an overview of Solid' CMC capabilities and how they fit into the company's overall strategy and the overall approach going forward?
Absolutely. Thank you so much for having us, and we're so please be participating in the Chardan conference and the manufacturing summit.
I think I'll start off first by just reiterating that there may be forward-looking statements made and we may need to disclaim any obligation update that in the future, even if they do change.
I think it's important [suite] to orient everyone around Solid as a new company. In December 2, 2022, we completed our merger with Avanti Biosciences and combined both companies' pipelines. People here might remember Solid
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
